<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594694</url>
  </required_header>
  <id_info>
    <org_study_id>747-213</org_study_id>
    <nct_id>NCT04594694</nct_id>
  </id_info>
  <brief_title>Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the effect of the investigational drug obeticholic acid (also known as&#xD;
      OCA) in combination with the investigational drug bezafibrate (BZF) in patients with Primary&#xD;
      Biliary Cholangitis (also known as PBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Alkaline Phosphatase (ALP) from baseline to Week 12 in the DB Treatment Period</measure>
    <time_frame>Baseline, Day 1, and Weeks 4, 8, and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates of ≥10%, ≥20%, and ≥40% reduction, and normalization of biochemical disease marker Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction, response rates and normalization of biochemical disease marker Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction, response rates and normalization of biochemical disease marker Gamma-Glutamyl Transpeptidase (GGT)</measure>
    <time_frame>Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction, response rates and normalization of biochemical disease marker Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction, response rates and normalization of biochemical disease markers total &amp; conjugated bilirubin</measure>
    <time_frame>Baseline, Day 1, and Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of bile acid synthesis, 7α hydroxy 4 cholesten-3 one (C4) and bile acids</measure>
    <time_frame>Baseline, Day 1, Weeks 2, 4, 6, 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of bile acid homeostasis and bile acids</measure>
    <time_frame>Baseline, Day 1, Weeks 2, 4, 6, 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events</measure>
    <time_frame>Baseline, Day 1, Weeks 2, 4, 6, 12, 24 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Treatment A: BZF 200 mg IR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bezafibrate (BZF): 200 mg IR Ocaliva (OCA) Placebo Bezafibrate (BZF) 400 mg Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: BZF 400 mg SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bezafibrate (BZF): 400 mg SR Ocaliva (OCA) Placebo Bezafibrate (BZF) 200 mg Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 200 mg IR Bezafibrate (BZF) 400 mg Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocaliva (OCA): 5 mg to 10 mg Bezafibrate (BZF) 400 mg SR Bezafibrate (BZF) 200 mg Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic acid</intervention_name>
    <description>5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily</description>
    <arm_group_label>Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR</arm_group_label>
    <arm_group_label>Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate 200 MG</intervention_name>
    <description>200 mg IR tablet of Bezafibrate once daily for the remainder of the study</description>
    <arm_group_label>Treatment A: BZF 200 mg IR</arm_group_label>
    <arm_group_label>Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCA Placebo</intervention_name>
    <description>One tablet daily for the remainder of the study</description>
    <arm_group_label>Treatment A: BZF 200 mg IR</arm_group_label>
    <arm_group_label>Treatment B: BZF 400 mg SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate 200 mg Placebo</intervention_name>
    <description>One tablet daily for the remainder of the study</description>
    <arm_group_label>Treatment B: BZF 400 mg SR</arm_group_label>
    <arm_group_label>Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate 400 MG</intervention_name>
    <description>400 mg SR tablet of Bezafibrate once daily for the remainder of the study</description>
    <arm_group_label>Treatment B: BZF 400 mg SR</arm_group_label>
    <arm_group_label>Treatment D: OCA 5 mg to 10 mg + BZF 400 mg SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate 400 mg Placebo</intervention_name>
    <description>One tablet daily for the remainder of the study</description>
    <arm_group_label>Treatment A: BZF 200 mg IR</arm_group_label>
    <arm_group_label>Treatment C: OCA 5 mg to 10 mg + BZF 200 mg IR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A definite or probable diagnosis of PBC&#xD;
&#xD;
          -  Qualifying ALP and/or bilirubin liver biochemistry values&#xD;
&#xD;
          -  Taking UDCA for at least 12 months or no UDCA for 3 months before Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of other concomitant liver diseases&#xD;
&#xD;
          -  Clinical complications of PBC&#xD;
&#xD;
          -  History or presence of hepatic decompensating events&#xD;
&#xD;
          -  Current or history of gallbladder disease&#xD;
&#xD;
          -  If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a&#xD;
             positive serum pregnancy test), or lactating&#xD;
&#xD;
          -  Treatment with commercially available OCA or participation in a previous study&#xD;
             involving OCA&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Harb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natasha Warner</last_name>
    <phone>+44-203-805-7557</phone>
    <email>Natasha.Warner@InterceptPharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erminia Cafasso</last_name>
    <email>erminia.cafasso@interceptpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>Perth</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libby Bambacas</last_name>
      <phone>+61 8204 7544</phone>
      <email>Libby.Bambacas@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kate Muller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Perth</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan Collins</last_name>
      <email>Megan.Collins@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Michael Wallace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Morgan</last_name>
      <email>Joanne.morgan@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Marc Le Mire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LKH-Universitaetsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Streit</last_name>
      <email>andrea.streit@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Peter Fickert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Bauer</last_name>
      <email>anita.bauer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Trauner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Smits</last_name>
      <phone>+32 2 555 4478</phone>
      <email>Francoise.Smits@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Schrijvers</last_name>
      <phone>+32 16 34 16 18</phone>
      <email>liliane.schrijvers@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Frederik Nevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zrinka Rob</last_name>
      <email>zrinka_rob@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Tonci Bozin</last_name>
      <email>tbozin@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ivica Grgurevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Milic</last_name>
      <email>Maja.Mijic@kb-merkur.hr</email>
    </contact>
    <investigator>
      <last_name>Tajana Filipec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zagreb University Hospital Center</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Knezevic Stromar</last_name>
      <email>ivana.stromar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Matea Majerovic</last_name>
      <email>Matea.majerovic@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marina Premuzic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o., Gastroenterologicka ambulance</name>
      <address>
        <city>Ostrava</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Floryk</last_name>
      <email>joned@email.cz</email>
    </contact>
    <investigator>
      <last_name>Vit Smajstrla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romana Hejdova</last_name>
      <email>hejdovaromana@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Vaclav Hejda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Sulkovskaja</last_name>
      <email>irina.sulkovskaja@kliinikum.ee</email>
    </contact>
    <investigator>
      <last_name>Riina Salupere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>940000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Haye</last_name>
      <email>delphine.haye@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Delphine Lefebvredenailly</last_name>
      <email>delphine.lefebvredenailly@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent Leroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Guigard</last_name>
      <phone>+33 4 76765987</phone>
      <email>Iguigard@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marina Bert</last_name>
      <phone>+33 7 76765987</phone>
      <email>mbert@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte Costentin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphnee Soret</last_name>
      <email>Daphnee.SORET@CHRU-LILLE.FR</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Brice</last_name>
      <email>Sylvie.BRICE@CHRU-LILLE.FR</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre Louvet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Dupuy</last_name>
      <email>julie.dupuy@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maude Charbonnier</last_name>
      <phone>(+33) 0557656311</phone>
      <email>maude.charbonnier@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Victor De Ledinghen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitalier Universitaire de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanessa Le Berre</last_name>
      <phone>05-49-44-30-44</phone>
      <email>vanessa.leberre@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laetitia Rouleau</last_name>
      <phone>05-49-44-30-44</phone>
      <email>laetitia.rouleau@chu-poitiers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christine Silvain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karima Ben Belkacem</last_name>
      <email>karima.benbelkacem@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Corpechot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna Brodhun</last_name>
      <email>johanna.brodhun@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Strassburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>Essen</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karolina Kleinsimlinghaus</last_name>
      <email>karolina.kleinsimlinghaus@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Lange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf UKE</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristin Aue-Raschka</last_name>
      <email>k.Aue-Raschka@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Schramm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Stoll</last_name>
      <email>stoll.olga@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Hans Heiner Wedemeyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Athens - Hippokration General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18794</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanouil Koullias</last_name>
      <email>koulliasman@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Spyridon Dourakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalliopi Azariadi</last_name>
      <email>kazariadis@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Georgios Dalekos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Budai Hepatologiai Centrum (BHC)</name>
      <address>
        <city>Budapest</city>
        <zip>1111</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaly Mahara</last_name>
      <phone>3614584660</phone>
      <email>makara.mihaly@hepatologia.hu</email>
    </contact>
    <investigator>
      <last_name>Gabor Horvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz</name>
      <address>
        <city>Békéscsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Opra</last_name>
      <phone>3614895200</phone>
      <email>andreaopra79@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Varga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DEOEC II. sz. Belgyógyászati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Fabian</last_name>
      <phone>36309722826</phone>
      <email>fabianmaria57@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Istvan Tornai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eilis O'Toole</last_name>
      <phone>353 1 (0) 410 3903</phone>
      <email>eiotoole@tcd.ie</email>
    </contact>
    <investigator>
      <last_name>Suzanne Norris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus - Liver unit</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vered Ben Hakoon</last_name>
      <email>v_ben-hakoon@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ella Veizman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orly Azulay</last_name>
      <email>orlyaz@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Eli Zuckerman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein-Karem Medical Center - Liver unit</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suha Sandouka</last_name>
      <email>shuha@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Rifat Safadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Surasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natali Band</last_name>
      <email>nataliaba@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ehud Zigmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center at Tel HaShomer</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dana Silverberg</last_name>
      <email>Dana.Silverberg@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ziv Ben-Ari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Joo Park</last_name>
      <phone>51-240-7869</phone>
      <email>juya0630@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jeong Heo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min A Lee</last_name>
      <phone>82-53-200-6138</phone>
      <email>minas0210@naver.com</email>
    </contact>
    <investigator>
      <last_name>Won Young Tak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ki Shin Ok</last_name>
      <phone>82-10-2592-0518</phone>
      <email>SHINOK74@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Seung Up Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mi-jin Park</last_name>
      <phone>+82-10-2813-4576</phone>
      <email>parkmijin.sc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yoon Jun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences, Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jurate Kondrackiene</last_name>
      <email>kondrackiene@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juozas Kupcinskas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vlinius University</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edita Kazenaite</last_name>
      <email>edita.kazenaite@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Arida Buivydiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine Bakker-Petters</last_name>
      <phone>+31 20 73 20393</phone>
      <email>m.w.peters@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ulrich Beuers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Locatie AZU</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda Wisselink</last_name>
      <phone>+31 88 75 745 94</phone>
      <email>l.e.wisselink@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Numan</last_name>
      <phone>+31 88 75 745 94</phone>
      <email>S.C.Numan@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Joep de Bruijne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetet i Oslo - Akershus Universitetssykehus (AHUS)</name>
      <address>
        <city>Loerenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Synnove Aure</last_name>
      <email>syau@ahus.no</email>
    </contact>
    <contact_backup>
      <last_name>Martine Saether</last_name>
      <email>saethm@ahus.no</email>
    </contact_backup>
    <investigator>
      <last_name>Kristin K Jorgensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacio Clinic Per La Recerca Biomedica</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Gonzalez</last_name>
      <phone>34 630 020 618</phone>
      <email>laragonzalez1989@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Moises Diago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pia Loqvist</last_name>
      <phone>46 8 585 871 22</phone>
      <email>pia.loqvist@sll.se</email>
    </contact>
    <investigator>
      <last_name>Staffan Wahlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull University Teaching Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Willcox</last_name>
      <email>julie.willcox@hey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Lynsey Corless</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Cellular Medicine, Newcastle University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Skinner</last_name>
      <email>victoria.skinner@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Emma Culver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6.</citation>
    <PMID>19501929</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

